Document is current

Article History

Accepted: 7 April 2025

First Online: 26 April 2025

Declarations

:

: The authors declare no conflicts of interest regarding the content of this article.

: This study was sponsored and funded by Fujian Baonuo Pharmaceutical R&D Co.

: All the protocol and documents were reviewed and approved by the Ethics Committee of Wuhan Pulmonary Hospital (no. 2021005). This study was registered at the Drug Clinical Trial Registration and Information Publicity Platform () with registration no. CTR20211003.

: All study participants provided written informed consent.

: All researchers, participants, institutions and sponsors consented to the submission of this report to the journal.

: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

: Not applicable.

: W.M. took responsibility for writing the manuscript and contributed to the pharmacokinetic analysis as well as data interpretation. P.Y. was responsible for the management of drugs in the study and manuscript submission. Y.H.G. participated in quality control throughout the study. P.Z.X. was involved in the management of biological samples. D.R.H. and L.G. were responsible for the conception and design of the study, data analysis and revision of the manuscript. All the authors have read and approved the final manuscript.